Vitamin D Insufficiency inVestigation Among hospitaLizeD Inpatients

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Angers

About this trial

Hypovitaminosis D is common in the adult population, it affects at least 1 billion people worldwide, and in particular 80% of the French population according to the National Institute for Public Health Surveillance. Hypovitaminosis D is accompanied or complicated by deleterious health manifestations such as bone, immune and cancer diseases, neuromuscular disorders and a propensity to fall, for example. Hypovitaminosis D has also been associated with more complicated care pathways (increase in the severity of the reason for hospitalization, length of hospitalization, risk of in-hospital death). Prevention of these clinical events depends on correcting vitamin D status.

In sick, dependent or fragile adults, natural intakes are generally insufficient. It is indeed accepted that hypovitaminosis D may not be treated effectively by dietary measures or by simple exposure to the sun in French latitudes. Drug supplementation is therefore necessary, with the objective of achieving a target concentration of circulating 25-hydroxyvitamin D (25 (OH) D) of 75 nmol / L (30 ng / mL) in this population.

Vitamin D supplementation, when properly conducted, corrects hypovitaminosis D, and has been associated with improved prognosis, especially life-saving, in therapeutic trials versus placebo. Such results lead the investigators to suggest that the identification and correction of hypovitaminosis D in hospitalized patients could represent a simple, effective and inexpensive strategy for improving hospital care pathways. In this perspective, the first step is to determine the prevalence, severity and clinical profile of hospitalized patients with hypovitaminosis D, as well as their course of care. To the investigators knowledge, there are no large-scale studies based on real-life data on this subject.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

≥ 18 years old

have had a dosage of circulating 25-hydroxyvitamin D (plasma or serum) in a HUGO establishment

consultant or hospitalized between 01/01/2015 and 12/31/2019 in one of the participating HUGOs.

Disqualifiers

None

Trial population

All consecutive patients meeting the eligibility criteria over the study period.

Trial design

Design model

Other

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Prevalence and depth of hypovitaminosis D

the prevalence of hypovitaminosis D will be calculated for each of the 3 definition thresholds for hypovitaminosis D found in the literature: ≤ 75 nmol/L, ≤ 50 nmol/L and ≤ 25 nmol/L.

Time frame
baseline

Secondary outcomes

1

Clinical profile

The clinical profile will be determine by the data provided by the physician during the hospitalization or the consultation

Time frame
baseline
2

Length of hospitalisation

determine whether the circulating 25-hydroxyvitamin D concentration is associated with the length of hospitalization in days

Time frame
baseline
3

Mortality

determine whether the circulating 25-hydroxyvitamin D concentration is associated with the death occurring during hospital stay.

Time frame
baseline, 14 and 28 days, 3 and 6 months after the dosage

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: